ストックスクリーナーアプリを入手
1.29
0.78%
0.01
アフターアワーズ：
1.25
-0.04
-3.10%
Cytosorbents Corp (CTSO) 最新ニュース
Millennium Management LLC Buys Shares of 33,280 Cytosorbents Co. (NASDAQ:CTSO) - Defense World
Cytosorbents announces voting results from annual meeting By Investing.com - Investing.com Canada
Cytosorbents announces voting results from annual meeting - Investing.com
CytoSorbents Warrants Expire Worthless as Stock Price Fails Threshold - Investing.com
Cytosorbents Co. (NASDAQ:CTSO) Shares Purchased by Northern Trust Corp - Defense World
Critical Care Leader CytoSorbents Reveals Growth Strategy at Jefferies Healthcare Conference - Stock Titan
Cytosorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented At EuroPCR 2025 - marketscreener.com
CytoSorbents device cuts bleeding in CABG patients - Investing.com
New Clinical Data: How CytoSorbents' Breakthrough Device Slashes Severe Bleeding Risk in Urgent Heart Surgery - Stock Titan
Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com - Defense World
Cytosorbents FY2025 EPS Forecast Lifted by HC Wainwright - Defense World
D. Boral Capital Reiterates “Buy” Rating for Cytosorbents (NASDAQ:CTSO) - Defense World
Cytosorbents (NASDAQ:CTSO) Earns Neutral Rating from HC Wainwright - Defense World
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2025 Earnings Call Transcript - Insider Monkey
Cytosorbents Corp’s Earnings Call: A Balanced Outlook - TipRanks
CytoSorbents (CTSO) Receives Neutral Rating from HC Wainwright & Co. | CTSO Stock News - GuruFocus
CytoSorbents (CTSO) Maintains Buy Rating with $10 Price Target | - GuruFocus
CytoSorbents (CTSO) Maintains Buy Rating with $10 Price Target | CTSO Stock News - GuruFocus
CytoSorbents: Q1 Earnings Snapshot - CT Insider
CytoSorbents Corp (CTSO) Q1 2025 Earnings Call Highlights: Navigating Challenges and ... - Yahoo Finance
CytoSorbents Corp (CTSO) Q1 2025 Earnings Call Highlights: Navigating Challenges and Strengthening Financials - GuruFocus
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - Defense World
CytoSorbents (CTSO) Targets Growth Amid Regulatory Challenges - GuruFocus
Earnings call transcript: CytoSorbents Q1 2025 misses earnings, stock dips - Investing.com
CytoSorbents Corp Q1 2025 Earnings: EPS of -$0.06 Beats Estimate, Revenue of $8.7M Misses Estimate - GuruFocus
CTSO Reports Q1 Revenue Below Expectations Amid Strategic Changes in Germany | CTSO Stock News - GuruFocus
CytoSorbents Corporation Q1 2025 Financial Results - TradingView
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Transcript : Cytosorbents Corporation, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
Raymond James Financial Inc. Makes New Investment in Cytosorbents Co. (NASDAQ:CTSO) - Defense World
CytoSorbents Corp (CTSO) Q1 2025 Earnings Report Preview: What t - GuruFocus
CytoSorbents's Earnings: A Preview - Nasdaq
CytoSorbents Corp (CTSO) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Cytosorbents (CTSO) Projected to Post Earnings on Wednesday - Defense World
Cytosorbents’ (CTSO) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com - Defense World
CytoSorbents (CTSO) Stock: Analyst Maintains "Buy" Rating with $ - GuruFocus
Behind Cytosorbents Corp’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Today’s watch list includes Cytosorbents Corp (NASDAQ:CTSO) stock - uspostnews.com
CytoSorbents (CTSO) Stock: Analyst Maintains - GuruFocus
Demystifying CytoSorbents: Insights From 4 Analyst Reviews - Benzinga
FDA denies CytoSorbents’ request for DrugSorb-ATR device - Investing.com
CytoSorbents: FDA issues denial letter for De Novo Request for DrugSorb-ATR - TipRanks
CytoSorbents (CTSO) Awaits FDA Approval for Breakthrough Device DrugSorb-ATR | CTSO Stock News - GuruFocus
CytoSorbents Provides Regulatory Update for DrugSorb-ATR - PR Newswire
Cytosorbents (NASDAQ:CTSO) versus Microbot Medical (NASDAQ:MBOT) Financial Analysis - Defense World
CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights - Longview News-Journal
CytoSorbents, Blood Purification Leader, Reveals Q1 2025 Results and Business Updates May 14 - Stock Titan
CytoSorbents secures $1.7M via NJ tax credit transfer - Investing.com
CytoSorbents Lands $1.7M Strategic Funding: New DrugSorb Product Launch and Manufacturing Expansion Ahead - Stock Titan
U.S. FDA Grants Breakthrough Designation To Cytosorb For Removal Of Ticagrelor During Cardiopulmonary Bypass In Emergent And Urgent Cardiothoracic Surgery - Reuters
4.52%
0.92%
大文字化:
|
ボリューム (24 時間):